4.7 Article

NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan

Journal

BIOMEDICINES
Volume 10, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines10102362

Keywords

nintedanib; Taiwan; idiopathic pulmonary fibrosis; lung function; real-world registry; pirfenidone

Funding

  1. Boehringer Ingelheim Taiwan Ltd.
  2. Boehringer Ingelheim (BI)

Ask authors/readers for more resources

This study is the first registry in Taiwan to observe the progression of idiopathic pulmonary fibrosis (IPF) under routine clinical practice. The findings indicate that antifibrotic medication is beneficial in delaying IPF progression, reducing acute exacerbations, and delaying mortality.
Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 +/- 9.1 years and 83.2% men) with IPF were collected over 2 years (2018-2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (+/- 1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available